{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:58:22Z","timestamp":1790909902646,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r\/r DLBCL) from the German third-party payer perspective. A budget impact model was established over a 6-year period. Estimation of the third-line population: partitioned survival model based on outcome data from peer-reviewed literature, a top-down approach based on population forecasts, and age-standardized incidences. Cost data were derived from the controlling department of a tertiary hospital and a German cost-of-illness study. In the scenario analysis, the budget impact of treating second-line DLBCL patients was calculated. One-way deterministic sensitivity analyses were conducted to test the robustness of the model. For the period 2021-2026, 788-867 (minimum population, min) and 1,068-1,177 (maximum population, max) adult third-line r\/r DLBCL patients were estimated. The budget impact ranged from \u20ac39,419,562; \u20ac53,426,514 (min; max) in year 0 to \u20ac122,104,097; \u20ac165,763,001 (min; max) in year 5. The scenario analysis resulted in a budget impact of \u20ac65,987,823; \u20ac89,558,611 (min; max) and \u20ac204,485,031; \u20ac277,567,601 (min; max) for years 0 and 5, respectively. This budget impact analysis showed a significant but reasonable financial burden associated with CAR T-cell therapy for a limited number of patients requiring individualized care. Further, this study presents challenges and future needs in data acquisition associated with cost analysis in personalized medicine. For comprehensive economic discussions, complementary cost-effectiveness analyses are required to determine the value of innovative therapies for r\/r DLBCL.<\/jats:p>","DOI":"10.1097\/hs9.0000000000000736","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T15:00:08Z","timestamp":1656946808000},"page":"e736","source":"Crossref","is-referenced-by-count":18,"title":["Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany"],"prefix":"10.1002","volume":"6","author":[{"given":"Daniela","family":"Skalt","sequence":"first","affiliation":[{"name":"Institute for Medical Information Processing, Biometry, and Epidemiology\u2014IBE, Ludwig-Maximilian University, Munich, Germany"},{"name":"Pettenkofer School of Public Health, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Moertl","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schoel","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"B\u00fccklein","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Weiglein","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Berger","sequence":"additional","affiliation":[{"name":"Institute for Medical Information Processing, Biometry, and Epidemiology\u2014IBE, Ludwig-Maximilian University, Munich, Germany"},{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7]]},"reference":[{"key":"R4-20231117","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network.","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"R7-20231117","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte.","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-20231117","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"R10-20231117","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"key":"R11-20231117","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","article-title":"CAR T-cell product performance in haematological malignancies before and after marketing authorisation.","volume":"21","author":"Elsallab","year":"2020","journal-title":"Lancet Oncol"},{"key":"R12-20231117","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor T cells in hematologic malignancies.","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"key":"R13-20231117","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"R14-20231117","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R15-20231117","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2019-125792","article-title":"A comparison of two-year outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in patients with refractory large B cell lymphoma.","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"R16-20231117","first-page":"116","article-title":"Neue Strategien in der Onkologie: CAR-T-Zellen erreichen die klinische Praxis.","author":"Siegmund-Schultze","year":"2019","journal-title":"Deutsches \u00c4rzteblatt"},{"key":"R17-20231117","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"R18-20231117","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.","volume":"21","author":"Roth","year":"2018","journal-title":"J Med Econ"},{"key":"R19-20231117","doi-asserted-by":"crossref","first-page":"e190035","DOI":"10.1001\/jamanetworkopen.2019.0035","article-title":"Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma.","volume":"2","author":"Whittington","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R20-20231117","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","article-title":"Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices\u2013budget impact analysis.","volume":"10","author":"Mauskopf","year":"2007","journal-title":"Value Health"},{"key":"R22-20231117","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"R25-20231117","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma.","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R26-20231117","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"R27-20231117","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study.","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"key":"R28-20231117","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/bloodadvances.2020001646","article-title":"The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.","volume":"4","author":"Assouline","year":"2020","journal-title":"Blood Adv"},{"key":"R29-20231117","article-title":"Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): A health economic perspective. Clinical Lymphoma Myeloma and Leukemia. 2021.","author":"Moertl"},{"key":"R30-20231117","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-140136","article-title":"Characteristics and treatment patterns of patients with relapsed\/refractory diffuse large B-cell lymphoma who received \u22653 lines of therapies.","volume":"136","author":"Xie","year":"2020","journal-title":"Blood"},{"key":"R34-20231117","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"R35-20231117","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma.","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"R37-20231117","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s10198-020-01219-3","article-title":"Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.","volume":"21","author":"Basic","year":"2020","journal-title":"Eur J Health Econ"},{"key":"R39-20231117","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1097\/HS9.0000000000000524","article-title":"Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future.","volume":"5","author":"Heine","year":"2021","journal-title":"HemaSphere"},{"key":"R40-20231117","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy.","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"R41-20231117","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"key":"R43-20231117","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41434-019-0074-7","article-title":"Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine.","volume":"27","author":"Elverum","year":"2020","journal-title":"Gene Ther"},{"key":"R44-20231117","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41591-021-01481-9","article-title":"Gene therapies should be for all.","volume":"27","year":"2021","journal-title":"Nat Med"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:09:18Z","timestamp":1702922958000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000736","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}